Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 26;10(1):71.
doi: 10.1038/s41572-024-00551-9.

Non-small-cell lung cancer

Lizza E L Hendriks #  1 , Jordi Remon #  2 , Corinne Faivre-Finn  3 , Marina C Garassino  4 , John V Heymach  5 , Keith M Kerr  6 , Daniel S W Tan  7 , Giulia Veronesi  8 , Martin Reck  9
Affiliations
Review

Non-small-cell lung cancer

Lizza E L Hendriks et al. Nat Rev Dis Primers. .

Erratum in

  • Author Correction: Non-small-cell lung cancer.
    Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, Tan DSW, Veronesi G, Reck M. Hendriks LEL, et al. Nat Rev Dis Primers. 2025 Jan 7;11(1):3. doi: 10.1038/s41572-025-00592-8. Nat Rev Dis Primers. 2025. PMID: 39773998 No abstract available.

Abstract

Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and radiotherapeutic techniques and a deeper biological understanding of NSCLC that has led to innovative systemic treatment options have improved the prognosis of patients with NSCLC. In non-metastatic NSCLC, the combination of various perioperative strategies and adjuvant immunotherapy in locally advanced disease seem to enhance cure rates. In metastatic NSCLC, the implementation of novel drugs might prolong disease control together with preserving quality of life. The further development of predictive clinical and genetic markers will be essential for the next steps in individualized treatment concepts.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Travis, W. D., Brambilla, E. & Riely, G. J. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J. Clin. Oncol. 31, 992–1001 (2013). - PubMed - DOI
    1. World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Use 2000–2025, fourth edition (WHO, 2021).
    1. Akhtar-Danseh, G. G., Akhtar-Danesh, N. & Finley, C. Uptake and survival effects of minimally invasive surgery for lung cancer: a population-based study. Eur. J. Surg. Oncol. 47, 1791–1796 (2021). - PubMed - DOI
    1. Bucknell, N. W. et al. Avoiding toxicity with lung radiation therapy: an IASLC perspective. J. Thorac. Oncol. 17, 961–973 (2022). - PubMed - DOI
    1. Uprety, D. & Surapaneni, M. Lung cancer management in low and middle-income countries—current challenges and potential solutions. Int. J. Cancer Care Deliv. https://doi.org/10.53876/001c.73042 (2023).

MeSH terms

LinkOut - more resources